Autoimmune hemophilia-like disease (hemorrhaphilia) due to anti-factor XIII (FXIII) antibodies (AH13) is a very rare, life-threatening bleeding disorder. A 77-year-old woman developed macrohematuria and a right renal pelvic hematoma. The coagulation times were not prolonged, but FXIII activity and antigen levels were severely and moderately reduced to 9 and 29% of normal values, respectively. Accordingly, the FXIII-specific activity turned out to be low. FXIII inhibitor and anti-FXIII-A subunit autoantibodies were detected by a 1:1 crossmixing test and immunoblot and immunochromatographic assays. She was therefore diagnosed with “definite AH13” and treated with plasma-derived FXIII concentrates to arrest the hemorrhage. In addition to a highly compressed inferior vena cava by a huge renal pelvic hematoma, deep vein thrombosis (DVT) and pulmonary thromboembolism (PE) were identified by systemic computed tomography. The patient was immediately started on anticoagulation therapy with low-dose heparin. Emboli disappeared quickly, probably because under-crosslinked thrombi caused by severe FXIII deficiency are vulnerable to fibrinolysis. After about 1.5 years, anti-FXIII-A subunit autoantibodies still remained despite the use of rituximab, steroid pulse therapy, oral prednisolone, and oral cyclophosphamide treatments. In conclusion, an extremely rare AH13 case complicated by DVT and PE was successfully managed by balancing anticoagulation therapy with hemostatic therapy.

Keywords:
Acquired hemorrhagic disorder, Anticoagulation therapy, Autoantibodies, Deep vein thrombosis, Factor XIII, Pulmonary embolism, Transglutaminase
1.
Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek: Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011;9:1404-1406.
2.
Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E: Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011;91:931-972.
3.
Ichinose A: Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012;95:362-370.
4.
Hsieh L, Nugent D: Factor XIII deficiency. Haemophilia 2008;14:1190-1200.
5.
Egbring R, Kröniger A, Seitz R: Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996;22:419-425.
6.
Ichinose A: Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011;37:382-388.
7.
Lorand L: Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins; in Green D (ed): Anticoagulants Physiologic, Pathologic, and Pharmacologic. Boca Raton, CRC Press, 1994, pp 169-191.
8.
Egbring R, Kröniger A, Seitz R: Erworbene inhibitoren gegen Faktor XIII. Hämostaseologie 1996;16:174-179.
9.
Ichinose A; Japanese Collaborative Research Group (JCRG) on AH13 Hemorrhagic Acquired Coagulopathies: Inhibitors of factor XIII/13 in older patients. Semin Thromb Hemost 2014;40:704-711.
10.
Ichinose A, Souri M: As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011;105:925-927.
11.
Ichinose A, Osaki T, Souri M: Clinical features of 32 new Japanese cases with autoimmune hemorrha-philia due to anti-factor XIII antibodies. Haemophilia 2015;21:653-658.
12.
Franchini M, Frattini F, Crestani S, Bonfanti C: Acquired FXIII inhibitors: a systematic review. J Thromb Thrombolysis 2013;36:109-114.
13.
Boehlen F, Casini A, Chizzolini C, Mansouri B, Kohler HP, Schroeder V, Reber G, de Moerloose P: Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013;109:479-487.
14.
Ichinose A: Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: a summary of 93 patients. Blood Rev 2017; 31:37-45.
15.
Ichinose A, Kohler HP, Philippou H: Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor XIII/13 deficiency. Thromb Haemost 2016;116:772-774.
16.
Souri M, Osaki T, Ichinose A: Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2B2 assembly and steal FXIII-A from native FXIII-A2B2. J Thromb Haemost 2015;13:802-814.
17.
Osaki T, Sugiyama D, Magari Y, Souri M, Ichinose A: Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90% of cases with autoimmune hemorrhaphilia XIII/13. Thromb Haemost 2015;113:1347-1356.
18.
Lim W, Moffat K, Hayward CP: Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004;2:1017-1019.
19.
Miesbach W: Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005;93:1001-1003.
20.
Almeida A, Khair K, Hann I, Liesner R: Unusual presentation of factor XIII deficiency. Haemophilia 2002;8:703-705.
21.
Stuijver DJ, Majoor CJ, van Zaane B, Souverein PC, de Boer A, Dekkers OM, Büller HR, Gerdes VE: Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest 2013;143:1337-1342.
22.
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sørensen HT: Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013;173:743-752.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.